Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Hospital de Clinicas de Porto Alegre
600 participants
Feb 1, 2002
INTERVENTIONAL
Conditions
Summary
Methylphenidate (MPH) is the first-line pharmacological treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Nevertheless, there is considerable interindividual variability regarding the dose required, tolerability and response rates to MPH. The aim of this study is to address the clinical and genetic predictors of MPH treatment outcomes in ADHD.
Eligibility
Inclusion Criteria3
- White Brazilian of European descent
- Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
- Eligibility to immediate-release MPH (IR-MPH) treatment
Exclusion Criteria5
- Contraindication for IR-MPH use
- Current stimulant treatment
- Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
- Current or past history of psychosis
- Estimated intelligence quotient score lower than 70
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02951754